ArticleThe Pan African medical journal2025
Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.The Pan African medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: breast cancer is a major public health concern in Morocco due to delayed diagnosis and treatment, largely due to its high incidence. It is the most prevalent cancer in women. This study aimed to report the epidemiological and the molecular profile of invasive breast carcinoma using surrogate immunohistochemical markers. Methods: during 24 months from 1 Results: this epidemiological study reveals that the mean age of patients was 52 ± 12.27 years. The most common histological type is invasive breast carcinoma of no special type, which accounts for 90.5% (n=1,410) of cases. Regarding Ellis and Elston modified Scarff-Bloom-Richardson (SBR) grade, grade III was the most common, 52.2% (n=521), followed by grade II, 44% (n=438), and grade I, 3.8% (n=38), as assessed by the SBR grade. The molecular classification results indicate that luminal B was the most common subtype at 52.2% (n=441), followed by triple-negative at 19.6% (n=166), with HER2 phenotype representing 17.4% (n=147) and luminal A at 10.8% (n=91). Conclusion: this study highlights that invasive breast carcinoma of no special type is the most common type, with grade III tumors being the most frequent. The majority of cases were luminal B, underscoring the need for targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.